Terns Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BST:430 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
05 Dec 24	Buy€104,513	Amy Burroughs	Individual	15,450	€6.76
12 Sep 24	Buy€4,530,995	Hongbo Lu	Individual	476,190	€9.52
01 Aug 24	Sell€43,716	Jill Quigley	Individual	6,143	€7.12
16 Jul 24	Sell€516,091	OrbiMed Advisors LLC	Company	56,164	€9.19
31 May 24	Buy€19,615	Mark Vignola	Individual	4,791	€4.09
31 May 24	Buy€19,615	Seokho Yoon	Individual	4,791	€4.09
03 Apr 24	Sell€2,020,608	Vivo Capital, LLC	Company	329,121	€6.45

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 430?
Owner Type	Number of Shares	Ownership Percentage
General Public	64,469	0.171%
Individual Insiders	308,682	0.821%
Hedge Funds	2,050,000	5.45%
Institutions	13,962,295	37.1%
VC/PE Firms	21,228,383	56.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.7%.

Top Shareholders

Top 25 shareholders own 97.99% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
19.9%	OrbiMed Advisors LLC	7,481,204	€35.9m	97.3%	0.6%
15.7%	Vivo Capital, LLC	5,899,372	€28.3m	121%	2.41%
12.7%	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	4,781,566	€22.9m	0%	4.72%
8.15%	VR Adviser, LLC	3,066,241	€14.7m	0%	1.95%
5.45%	Fairmount Funds Management LLC	2,050,000	€9.8m	0%	1.71%
4.94%	Deerfield Management Company, L.P. Series C	1,860,000	€8.9m	-20.7%	0.25%
4.69%	BML Capital Management, LLC	1,764,274	€8.5m	0%	10.63%
3.75%	Shanghai Liyi Investment Management Partnership (Limited Partnership)	1,411,206	€6.8m	0%	3.16%
3.35%	RA Capital Management, L.P.	1,261,435	€6.0m	0%	0.12%
3.29%	Suvretta Capital Management, LLC	1,238,800	€5.9m	0%	0.21%
2.33%	Antara Capital LP	874,600	€4.2m	-18.6%	0.71%
1.9%	Decheng Capital LLC	714,285	€3.4m	0%	1.17%
1.86%	Ikarian Capital, LLC	700,000	€3.4m	0%	1.13%
1.75%	Barclays PLC Private Banking & Investment Banking Investment	658,222	€3.2m	4,920%	0.01%
1.34%	Point72 Asset Management, L.P.	502,428	€2.4m	306%	0.01%
1.07%	Affinity Asset Advisors, LLC	401,268	€1.9m	0%	1.14%
0.98%	The Vanguard Group, Inc.	367,529	€1.8m	-15.1%	no data
0.86%	Armistice Capital LLC	323,016	€1.5m	0%	0.04%
0.77%	Samsara BioCapital LLC	289,068	€1.4m	0%	0.3%
0.76%	Weidong Zhong	285,714	€1.4m	0%	no data
0.74%	Millennium Management LLC	277,688	€1.3m	214%	no data
0.56%	Driehaus Capital Management LLC	210,074	€1.0m	499%	0.01%
0.49%	Renaissance Technologies LLC	184,416	€883.8k	172%	no data
0.4%	BlackRock, Inc.	149,528	€716.6k	-79.7%	no data
0.28%	Boothbay Fund Management, LLC	106,712	€511.4k	0%	0.02%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/11/13 14:25
End of Day Share Price	2022/08/16 00:00
Earnings	2022/09/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Terns Pharmaceuticals, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	BMO Capital Markets Equity Research
Corinne Johnson	Goldman Sachs
Corinne Johnson	Goldman Sachs